Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + cisplatin + doxorubicin + mitomycin c
- Development stage
- Unknown
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This regimen is a multi-agent chemotherapy combination consisting of four cytotoxic drugs: 5-fluorouracil, cisplatin, doxorubicin, and mitomycin C. Each component has a distinct mechanism of action targeting cancer cell proliferation: - **5-Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks and induces apoptosis. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II. - **Mitomycin C** acts as an alkylating agent causing DNA crosslinking. This combination has been studied primarily in advanced solid tumors such as non-small cell lung cancer[1], gastric cancer[2][3], and biliary tract cancers[6]. The regimen aims to maximize tumor response by combining agents with complementary mechanisms but carries significant risk of myelosuppression and other toxicities.
- Other names
- 5-FU + cisplatin + doxorubicin + mitomycin CFAM (when referring to 5-fluorouracil, doxorubicin, and mitomycin C)FAMM (occasionally used for this four-drug combination)
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 5-fluorouracil + cisplatin + doxorubicin + mitomycin c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + cisplatin + doxorubicin + mitomycin c.